The ‘PDMED’ trial

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial.

PD MED Collaborative Group*

Summary
Background Whether initial treatment for Parkinson’s disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors (MAOBI) is uncertain. We aimed to establish which of these three classes of drug, as initial treatment, provides the most effective long-term control of symptoms and best quality of life for people with early Parkinson’s disease. PDMED

Published Online
June 11, 2014 http://dx.doi.org/10.1016/ S0140-6736(14)60683-8

See Online/Comment http://dx.doi.org/10.1016/ http://dx.doi.org/10.1016/ S0140-6736(14)60962-4

*Members listed at end of paper

Correspondence to:
PD MED Trial Office, Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, Robert Aitken Institute for Clinical Research, University of Birmingham, Birmingham
B15 2TT, UK PD-trials@bham.ac.uk